The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats.
Fenofibrate is a drug that has been suggested to inhibit weight gain by increasing the catabolism of fatty acid in the hepatic mitochondria. We hypothesized that fenofibrate induces an increase in energy expenditure in the hepatic mitochondria, which results in the reduction of adipose tissue. In this study we measured hepatic uncoupling protein (UCP)-2, -3, core temperatures and abdominal fat composition with MRI in Otsuka Long-Evans Tokushima Fatty rats. The fenofibrate group (n=7) was fed fenofibrate (320 mg/kg) mixed chow. The control group (n=7) was fed chow only. The body weight (531.6+/-7.6 g) of the fenofibrate group was significantly lower than that (744.3+/-14.9 g) of the control group (p<0.005). The areas of visceral and subcutaneous fat in the fenofibrate group (11.0+/-0.9 cm(2), 4.2+/-0.3 cm(2)) were significantly less than those in the control group (21.0+/-0.7 cm(2), 7.4+/-0.4 cm(2)) (p=0.046, respectively). The esophageal and rectal temperatures of the fenofibrate group (37.7+/-0.1 degrees C, 33.1+/-0.2 degrees C) were significantly higher than those of the control group (37.3+/-0.1 degrees C, 32.2+/-0.1 degrees C) (p=0.025, p=0.005). There was de novo expression of UCP-3 in the liver of the fenofibrate group. These data suggest that increased energy dissipation, via hepatic UCP-3 by fenofibrate, contribute to decreased weight gain in obese rats.
Park
Mi-Kyoung
MK
Department of Internal Medicine, Medical Science Research Institute, Dong-A University College of Medicine, 1 3-ga Dongdaesin-dong, Seo-gu, Busan, Korea.
Lee
Hye-Jeong
HJ
Hong
Sook-Hee
SH
Choi
Sun-Seob
SS
Yoo
Young Hyun
YH
Lee
Kyung Il
KI
Kim
Duk Kyu
DK
D000273:Adipose Tissue / Q000187:drug effects*; D000818:Animals; D001831:Body Temperature / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D004734:Energy Metabolism / Q000187:drug effects*; D011345:Fenofibrate / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D008099:Liver / Q000187:drug effects / Q000503:physiopathology*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D009765:Obesity / Q000503:physiopathology*; D051381:Rats; D020334:Rats, Inbred OLETF
D000960:Hypolipidemic Agents; D011345:Fenofibrate